	US 12,428,376 B2
	Therapeutic compounds and compositions
Francesco G. Salituro, Marlborough, MA (US); Jeffrey O. Saunders, Lincoln, MA (US); and Shunqi Yan, Irvine, CA (US)
Assigned to Agios Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Agios Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Nov. 10, 2023, as Appl. No. 18/507,013.
Application 18/507,013 is a division of application No. 17/195,243, filed on Mar. 8, 2021, granted, now 11,866,411.
Application 17/195,243 is a division of application No. 16/243,247, filed on Jan. 9, 2019, granted, now 10,988,448, issued on Apr. 27, 2021.
Application 16/243,247 is a division of application No. 16/010,717, filed on Jun. 18, 2018, abandoned.
Application 15/412,976 is a division of application No. 14/286,088, filed on May 23, 2014, abandoned.
Application 14/286,088 is a division of application No. 12/826,630, filed on Jun. 29, 2010, granted, now 8,785,450, issued on Jul. 22, 2014.
Application 16/010,717 is a continuation of application No. 15/412,976, filed on Jan. 23, 2017, granted, now 10,029,987, issued on Jul. 24, 2018.
Claims priority of provisional application 61/292,360, filed on Jan. 5, 2010.
Claims priority of provisional application 61/221,430, filed on Jun. 29, 2009.
Prior Publication US 2024/0360083 A1, Oct. 31, 2024
Int. Cl. C07D 401/12 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5513 (2006.01); A61P 35/00 (2006.01); C07D 215/36 (2006.01); C07D 215/40 (2006.01); C07D 239/42 (2006.01); C07D 241/20 (2006.01); C07D 243/08 (2006.01); C07D 271/12 (2006.01); C07D 277/64 (2006.01); C07D 277/68 (2006.01); C07D 295/192 (2006.01); C07D 319/18 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 407/12 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)

CPC C07D 215/36 (2013.01) [A61K 31/497 (2013.01); A61K 31/5513 (2013.01); C07D 215/40 (2013.01); C07D 239/42 (2013.01); C07D 241/20 (2013.01); C07D 243/08 (2013.01); C07D 271/12 (2013.01); C07D 277/64 (2013.01); C07D 277/68 (2013.01); C07D 295/192 (2013.01); C07D 319/18 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 407/12 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); Y02P 20/582 (2015.11)]

5 Claims

1. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein

W, X, Y and Z are each independently selected from CH or N;

D and D¹are independently selected from a bond or NR^b;

A is optionally substituted bicyclic heteroaryl;

L is a bond, —C(O)—, —(CR^cR^c)_m—, —OC(O)—, —(CR^cR^c)_m—OC(O)—, —(CR^cR^c)_m—C(O)—, —NR^bC(S)—, or —NR^bC(O)—;

R¹is selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; each of which is substituted with 0-5 occurrences of R^d;

each R³is independently selected from halo, haloalkyl, alkyl, hydroxyl and —OR^aor two adjacent R³taken together with the carbon atoms to which they are attached form an optionally substituted cyclyl;

each R^ais independently selected from alkyl, acyl, hydroxyalkyl and haloalkyl;

each R^bis independently selected from hydrogen and alkyl;

each R^cis independently selected from hydrogen, halo, alkyl, alkoxy and haloalkoxy or two R^ctaken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;

each R^dis independently selected from halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, —C(O)R^a, —OC(O)R^a, —C(O)OR^a, —SR^a, —NR^aR^band —OR^a, or two R^dtaken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;

n is 0, 1, or 2;

m is 1, 2 or 3; and

h is 0 and g is 2 or h is 2 and g is 0.